Profile data is unavailable for this security.
About the company
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
- Revenue in USD (TTM)76.45m
- Net income in USD-28.09m
- Incorporated1997
- Employees171.00
- LocationNeuropace Inc455 N. Bernardo AvenueMOUNTAIN VIEW 94043United StatesUSA
- Phone+1 (650) 237-2700
- Fax+1 (650) 237-2701
- Websitehttps://www.neuropace.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orchestra Biomed Holdings Inc | 2.65m | -57.69m | 205.77m | 56.00 | -- | 4.47 | -- | 77.74 | -1.60 | -1.60 | 0.0734 | 1.22 | 0.0276 | 1.04 | 26.34 | 47,267.86 | -60.19 | -- | -74.93 | -- | 92.71 | -- | -2,179.34 | -- | 4.21 | -- | 0.00 | -- | -21.88 | -- | -37.91 | -- | -- | -- |
| Inogen Inc | 331.52m | -52.69m | 218.45m | 834.00 | -- | 1.18 | -- | 0.6589 | -2.25 | -2.25 | 14.09 | 7.78 | 1.02 | 7.81 | 8.03 | 397,506.00 | -16.21 | -8.23 | -20.38 | -9.53 | 44.22 | 44.54 | -15.89 | -10.31 | 2.34 | -- | 0.00 | -- | -16.32 | -2.49 | -22.30 | -- | 26.34 | -- |
| Utah Medical Products, Inc. | 44.08m | 15.26m | 224.52m | 169.00 | 15.10 | 1.79 | 12.23 | 5.09 | 4.27 | 4.27 | 12.36 | 36.09 | 0.3378 | 1.93 | 12.23 | 260,816.60 | 11.69 | 12.69 | 12.05 | 13.19 | 58.80 | 61.57 | 34.62 | 30.51 | 26.94 | -- | 0.00 | 37.05 | -3.93 | 3.64 | 0.9834 | 1.65 | 9.71 | 1.86 |
| Electromed Inc | 57.06m | 6.47m | 235.92m | 174.00 | 38.69 | 5.72 | 32.25 | 4.13 | 0.7256 | 0.7256 | 6.40 | 4.91 | 1.23 | 3.37 | 2.42 | 327,931.00 | 13.91 | 8.64 | 16.22 | 10.09 | 76.62 | 76.26 | 11.34 | 8.06 | 5.06 | -- | 0.00 | 0.00 | 13.83 | 11.82 | 62.67 | 21.06 | -22.23 | -- |
| Trubridge Inc | 337.67m | -58.25m | 238.95m | 3.22k | -- | 1.38 | -- | 0.7076 | -4.09 | -4.09 | 23.67 | 11.57 | 0.8126 | 183.56 | 5.84 | 104,900.30 | -14.40 | 1.25 | -16.50 | 1.41 | 49.31 | 50.40 | -17.72 | 1.56 | 1.78 | 0.8055 | 0.5052 | 45.06 | 3.91 | 3.89 | -387.73 | -- | 88.71 | -- |
| LifeMD Inc | 193.06m | -25.61m | 245.06m | 207.00 | -- | -- | -- | 1.27 | -0.6409 | -0.6409 | 4.85 | -0.1847 | 3.41 | 6.21 | 36.89 | 932,652.80 | -39.18 | -153.05 | -240.82 | -526.91 | 89.64 | 83.66 | -11.49 | -45.44 | 0.7805 | -8.83 | 1.49 | -- | 28.15 | 78.90 | 51.27 | -- | 143.64 | -- |
| Atlantic International Corp | 313.06m | -68.07m | 253.24m | 7.00 | -- | 14.11 | -- | 0.8089 | -5.55 | -5.55 | 12.45 | 0.358 | 4.44 | -- | 10.48 | 44,723,330.00 | -96.45 | -71.97 | -233.48 | -106.09 | 10.81 | 61.01 | -21.74 | -1,471.82 | -- | -1.64 | 0.8328 | -- | -100.00 | -- | -37.43 | -- | -- | -- |
| Pulmonx Corp | 79.30m | -57.11m | 253.51m | 279.00 | -- | 2.70 | -- | 3.20 | -1.47 | -1.47 | 2.04 | 2.38 | 0.45 | 1.24 | 7.29 | 284,236.60 | -32.41 | -26.27 | -36.42 | -28.97 | 74.16 | 71.95 | -72.01 | -93.76 | 6.77 | -- | 0.2839 | -- | 27.98 | 27.98 | -3.26 | -- | 20.62 | -- |
| Anika Therapeutics Inc | 164.17m | -97.52m | 255.27m | 357.00 | -- | 1.42 | -- | 1.55 | -6.64 | -6.64 | 11.14 | 12.24 | 0.5868 | 1.47 | 5.21 | 459,854.30 | -34.86 | -5.41 | -38.55 | -5.87 | 62.70 | 60.70 | -59.40 | -12.60 | 3.78 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
| Zynex Inc | 193.67m | 4.82m | 258.27m | 1.10k | 54.76 | 7.33 | 27.62 | 1.33 | 0.1481 | 0.1481 | 5.91 | 1.11 | 1.40 | 2.57 | 7.05 | 176,059.10 | 3.48 | 14.58 | 4.06 | 17.52 | 80.20 | 79.62 | 2.49 | 10.44 | 3.15 | 4.15 | 0.6246 | -- | 16.54 | 42.01 | -42.91 | 0.3741 | 2.19 | -- |
| Neuropace Inc | 76.45m | -28.09m | 268.63m | 171.00 | -- | 27.28 | -- | 3.51 | -0.9924 | -0.9924 | 2.70 | 0.3299 | 0.7817 | 1.83 | 6.69 | 447,087.70 | -28.72 | -- | -33.44 | -- | 73.83 | -- | -36.74 | -- | 4.77 | -4.06 | 0.8578 | -- | 43.72 | -- | 30.00 | -- | -- | -- |
| AngioDynamics, Inc. | 292.73m | -243.03m | 282.41m | 748.00 | -- | 1.45 | -- | 0.9648 | -6.04 | -6.04 | 7.25 | 4.79 | 0.7434 | 2.27 | 6.55 | 391,344.90 | -61.72 | -16.38 | -74.39 | -18.70 | 51.71 | 52.95 | -83.02 | -30.49 | 1.41 | -- | 0.00 | -- | -10.28 | 2.35 | -251.53 | -- | 13.09 | -- |
| OraSure Technologies, Inc. | 224.26m | 11.37m | 287.19m | 638.00 | 25.57 | 0.6748 | 11.73 | 1.28 | 0.1506 | 0.1506 | 3.01 | 5.71 | 0.4862 | 2.64 | 5.58 | 351,509.40 | 2.72 | 0.7238 | 2.94 | 0.8212 | 42.26 | 46.94 | 5.59 | 1.13 | 11.20 | -- | 0.0004 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
| Clearpoint Neuro Inc | 30.43m | -18.15m | 305.91m | 107.00 | -- | 10.55 | -- | 10.05 | -0.6912 | -0.6912 | 1.16 | 1.05 | 0.7242 | 1.50 | 9.66 | 284,383.20 | -43.19 | -34.75 | -51.20 | -39.67 | 60.38 | 64.75 | -59.64 | -76.91 | 3.61 | -- | 0.00 | -- | 16.56 | 26.64 | -34.40 | -- | 75.30 | -- |
| Cerus Corp | 197.91m | -19.73m | 310.14m | 288.00 | -- | 5.80 | -- | 1.57 | -0.1076 | -0.1076 | 1.08 | 0.2882 | 1.00 | 1.97 | 7.88 | 687,194.40 | -10.01 | -25.99 | -15.26 | -40.62 | 60.52 | 61.90 | -10.00 | -35.81 | 1.92 | -1.19 | 0.6057 | -- | -0.8061 | 19.69 | 12.37 | -- | 32.07 | -- |
| Delcath Systems Inc | 22.64m | -34.12m | 314.94m | 76.00 | -- | 32.20 | -- | 13.91 | -1.36 | -1.36 | 0.8343 | 0.3059 | 0.5714 | 0.9094 | 6.34 | 297,947.40 | -86.11 | -116.57 | -156.17 | -243.21 | 81.31 | 71.02 | -150.70 | -1,235.37 | 1.03 | -172.60 | 0.1892 | -- | -24.05 | -9.53 | -30.60 | -- | -5.26 | -- |
Data as of Nov 22 2024. Currency figures normalised to Neuropace Inc's reporting currency: US Dollar USD
38.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 2.49m | 8.53% |
| Soleus Capital Management LP (Investment Management)as of 30 Sep 2024 | 2.43m | 8.33% |
| Kent Lake Pr LLCas of 30 Sep 2024 | 1.25m | 4.28% |
| Kent Lake Capital LLCas of 30 Jun 2024 | 1.14m | 3.92% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 965.92k | 3.31% |
| Millennium Management LLCas of 30 Sep 2024 | 739.99k | 2.53% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 625.27k | 2.14% |
| Nantahala Capital Management LLCas of 30 Sep 2024 | 607.89k | 2.08% |
| Armistice Capital LLCas of 30 Sep 2024 | 480.00k | 1.64% |
| DWS Investments (UK) Ltd.as of 30 Sep 2024 | 412.26k | 1.41% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
